Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax Combination Regimen in Newly Diagnosed Acute Lymphoblastic Leukemia
NCT07795099Not yet recruiting
- Sponsor
- Lanzhou University
- Start
- Aug 2026
- Primary completion
- Aug 2029
01
Overview
Open-label trial of lisaftoclax in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Lanzhou University. Primary endpoint: Complete Remission Rate at Day 35. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07795099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795099.